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Abstract
Purpose Acute monoamine depletion paradigms using
alpha-methyl-para-tyrosine (AMPT) combined with single
photon emission computed tomography (SPECT) have
been used successfully to evaluate disturbances in central
dopaminergic neurotransmission. However, severe side
effects due to relatively high doses (4,500 to 8,000 mg) of
AMPT have been reasons for study withdrawal. Thus, we
assessed the effectiveness and tolerability of two alternative
procedures, using lower doses of AMPT.
Methods Six healthy subjects underwent three measure-
ments of striatal dopamine D2 receptor (D2R)-binding
potential (BPND) with SPECT and the selective radiolabeled
D2R antagonist [
123I]IBZM. All subjects were scanned in
the absence of pharmacological intervention (baseline) and
after two different depletion procedures. In the first
depletion session, over 6 h, subjects were administered
1,500 mg of AMPT before scanning. In the second
depletion session, over 25 h, subjects were administered
40 mg AMPT/kg body weight. We also administered the
Subjective Well-being Under Neuroleptic Treatment Scale,
a self-report instrument designed to measure the subjective
experience of patients on neuroleptic medication.
Results We found no change of mean D2R BPND after the
first and short AMPT challenge compared to the baseline.
However, we found a significant increase in striatal D2R
BPND binding after the AMPT challenge adjusted for
bodyweight compared to both other regimen. Although
subjective well-being worsened after the prolonged AMPT
challenge, no severe side effects were reported.
Conclusions Our results imply a low-dosage, suitable
alternative to the common AMPT procedure. The probability
of side effects and study withdrawal can be reduced by this
procedure.
Keywords AMPT. Dopamine . [123I]IBZM . SPECT. SWN
Introduction
Several neuropsychiatric disorders have been associated
with disturbances of the catecholaminergic neurotransmit-
ters dopamine (DA) and norepinephrine (NE), including
schizophrenia [1], mood disorders [2, 3] and Parkinson’s
disease [4]. Strategies to increase our knowledge of these
neurotransmitter systems combining pharmacologic chal-
lenges with neuroimaging techniques like positron emission
tomography (PET) and single photon emission computed
tomography (SPECT) are extensively used. The develop-
ment of such experimental procedures has allowed for the
investigation of associations between the function of
neurotransmitters and neuropsychiatric disorders. For ex-
ample, employing such a challenge paradigm, it has been
Eur J Nucl Med Mol Imaging (2008) 35:1350–1356
DOI 10.1007/s00259-008-0739-8
E. Boot (*) : J. R. Zinkstok : L. de Haan :D. H. Linszen :
T. A. van Amelsvoort
Department of Psychiatry, Academic Medical Centre (AMC),
University of Amsterdam,
Meibergdreef 5,
1070 AWAmsterdam, The Netherlands
e-mail: h.j.boot@amc.uva.nl
J. Booij
Department of Nuclear Medicine, AMC,
Amsterdam, The Netherlands
G. Hasler
Department of Psychiatry, University Hospital,
Zürich, Switzerland
E. Boot
De Bruggen, Centre for People with Intellectual Disability,
Zwammerdam, The Netherlands
shown that there is an increased occupancy of DA D2
receptors (D2R) by endogenous DA in schizophrenic
patients compared to the controls [5]. In addition, mono-
amine depletion studies demonstrate that, although mono-
amine systems are probably important in the vulnerability
to mood lability, there is no simple direct causal relation
between catecholamines and mood, as proposed in the
monoamine hypothesis of mood disorders [3, 6, 7].
Catecholamine depletion paradigms have been used most
frequently in two ways. First, dietary restriction of the
catecholamine precursors phenylalanine and tyrosine has
been used in the so-called acute tyrosine depletion or
phenylalanine/tyrosine depletion (APTD) [6]. APTD involves
the restriction of the precursor amino acid, phenylalanine and
tyrosine, intake during 1 day, followed by the consumption
of an amino acid mixture that lacks phenylalanine and
tyrosine the next morning [6]. As this mixture stimulates
protein synthesis, which requires phenylalanine and tyrosine,
less of the amino acids phenylalanine and tyrosine are
available for the brain [6]. Although the biochemical effects
of this procedure in the brain remain unclear, it is believed
that APTD mainly affects DA synthesis [6]. Experience with
APTD challenges in combination with neuroimaging techni-
ques is limited, and we are aware of only two such studies.
In one PET study in seven healthy men, APTD induced an
increased [11C]raclopride binding by a mean of 6% [8].
Second, Leyton et al. [9] presented a PET study in eight
healthy men that provided evidence for APTD to decrease
amphetamine-induced DA release. Except for limited expe-
riences, disadvantages of APTD include an unpalatable taste
[10] and nausea [11], and study subjects tend to report that
they feel less good after this diet [12]. Another way to induce
catecholamine depletion is by administration of alpha-
methyl-para-tyrosine (AMPT). AMPT is a competitive
inhibitor of the rate-limiting enzyme of catecholamine
synthesis and tyrosine hydroxylase [13], and affects both
DA and NE synthesis [6]. It has been suggested that AMPT
produces a substantially greater impairment in DA release
than tyrosine depletion does [11]. However, side effects,
which are dose-related, may be serious and can be reason for
withdrawal. For example, severe side effects that have been
reported previously include serious psychiatric symptoms
[14], crystalluria and acute dystonia [5, 15]. Common AMPT
depletion procedures involve a 25- to 48-h study period in
which study subjects administer a total amount of 4,500–
8,000 mg AMPT [6]. Nevertheless, other studies showed
significant depletion effects on indirect dopaminergic
markers including measures of peripheral DA, its metabolites
and the hormone prolactin (PRL) after lower doses of AMPT
[16, 17]. For this, it could be hypothesized that, to induce
measurable effects of DA depletion with PET or SPECT,
lower dosages than the common 4,500–8,000 mg AMPT
may be sufficient.
Moreover, lower doses of AMPT could possibly reduce
side effects as well and would therefore allow testing
subjects in complex neuropsychological tasks and imaging
experiments. To estimate the effects of reduced dopaminer-
gic neurotransmission, we administered a self-report instru-
ment, the Subjective Well-being Under Neuroleptic
Treatment Scale (SWN) [18–20]. For example, initial
studies using this instrument provided evidence that
negative subjective experience is related to high DA D2R
occupancy in patients treated with antipsychotic medica-
tion, reflecting a hypodopaminergic state [21, 22].
The aim of this study was to assess the effectiveness and
tolerability of two alternative procedures for the commonly used
acute AMPT depletion challenge paradigm and simultaneous
D2R SPECT imaging, using relatively low doses of AMPT.
Materials and methods
Subjects
The study protocol was approved by the Ethics Committee
of the Academic Medical Centre of Amsterdam. Each
participant gave written informed consent after explaining
the full study procedure. Six healthy volunteers older than
18 years but younger than 40 years were included. The
exclusion criteria were (1) current or past psychiatric
history, (2) current or previous exposure to antipsychotic
or stimulant medication, (3) lifetime history of alcohol or
substance abuse or dependence, (4) concomitant or past
severe medical conditions and (5) pregnancy, based on a
clinical interview and the urine ßHCG test.
Depletion regimen
Each subject was scanned three times, once in the baseline
state (D1) and twice after DA depletion (D2, D3) with an
interval ranging from one to nine and from 49 to 110 weeks,
respectively. DA depletion was induced by oral adminis-
tration of AMPT. In a short AMPT challenge session using
a low fixed dose of AMPT (D2), the total AMPT dose
administered was 1,500 mg over 4 h. The first dose
(500 mg) was given on the morning (D2T0). Subsequently,
500 mg AMPT was administered 2 h after baseline (D2T2)
and 4 h after baseline (500 mg, D2T4). Scans were acquired
1 h after the last AMPT dose (D2T5).
In the second and more prolonged challenge session
(D3), DA depletion was induced by oral administration of
AMPT over 24 h. The exact AMPT dose was calculated on
a per weight basis (40 mg/ kg body weight). The overall
AMPT dose was spread equally in 250-mg capsules over
four time points. Three doses were given 1 day before the
scan: at baseline (D3T0), 6 h after baseline (D3T6) and 12 h
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after baseline (D3T12). The last AMPT dose was given 24 h
after D3T0 (D3T24) and 1 h before the beginning of the
scanning session (D3T25). To prevent the formation of
AMPT crystals in the urine, subjects were instructed to
drink plenty of fluids.
SPECT protocol
All subjects took potassium iodide orally (three doses of
40 mg on the day before imaging and 80 mg just before
imaging) to block thyroid uptake of free radioactive iodide.
The subjects underwent three measurements of D2R-binding
potential (BPND) [23], with SPECT and the selective iodine-
123-labeled D2R antagonist (S)-(–)-3-iodo-2-hydroxy-
6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide
([123I]IBZM), using the sustained equilibrium/constant infu-
sion technique [24]. A total [123I]IBZM dose (specific
activity>200 MBq/nmol and radiochemical purity>95%) of
approximately 56 MBq was given as a bolus, followed by a
continuous infusion for the duration of the experiment
(180 min). The bolus to hourly infusion ratio was approx-
imately 4.0 [25]. This protocol of administration induces a
state of sustained binding equilibrium after 120 min [25].
SPECT data were acquired for approximately 60 min, from
120 to 180 min after the initiation of [123I]IBZM adminis-
tration. SPECT studies were performed using a 12-detector
single slice brain-dedicated scanner (Neurofocus 810, which
is an upgrade of the Strichmann Medical Equipment) with a
full-width at half maximum resolution of approximately
6.5 mm, throughout the 20 cm field-of-view (http://www.
neurophysics.com). After positioning of the subjects with the
head parallel to the orbitomeatal line, axial slices parallel and
upward from the orbitomeatal line to the vertex were
acquired in 5 mm steps. Each acquisition consisted of
approximately 12–13 slices with 5 min scanning time per
slice, acquired in a 64×64 matrix. The energy window was
set at 135–190 keV. At the day of the imaging session, the
participants were not allowed to consume coffee or alcohol
because they have been associated with altered striatal DA
release [26]. The first scan was obtained in the absence of
pharmacological intervention (baseline scan), on the first day
of the study (D1). The second and third scans were
performed after DA depletion induced by oral administration
of AMPT, as described previously. Thus, three measures of
striatal D2R binding were obtained in each subject: at
baseline (D1), in the short session (D2) after 1,500 mg of
AMPT and in the prolonged depleted state (D3) after a body-
weight-adjusted AMPT dose.
Image reconstruction and analysis
SPECT data were reconstructed and analyzed blind to
clinical data by the same experienced investigator (J.B.).
Attenuation correction of all images was performed as
earlier described [27]. Images were reconstructed in 3D
mode (http://www.neurophysics.com). For quantification, a
region-of-interest (ROI) analysis was performed. Fixed
ROIs for the striatum and occipital cortex were used. For
the right and left striatum and left and right occipital cortex,
a template with irregular ROIs, according to the contour of
the striatum and occipital cortex, was positioned on four
consecutive axial slices with highest striatal activity.
Individual variation required movement of the fixed ROIs,
without changing size and shape, within the template for
optimal fitting. For the right occipital and left occipital
cortices, irregular ROIs were drawn in one template. Mean
striatal and mean occipital binding densities were averaged
from right and left ROIs. BPND was calculated as the ratio
of specific to non-specific activity (total activity in striatum
minus activity in occipital cortex, divided by activity in
occipital cortex).
Prolactin
Blood samples were taken at D2T0, D2T3 and D2T6 at the
short scanning day and at D3T26 at the prolonged scanning
day for determination of plasma PRL levels. The cannula
was flushed with NaCl 0.9% to ensure that the cannula
remained open. PRL was measured by time-resolved
fluoroimmunoassay (DELFIA Prolactin, Wallac Oy, Turku,
Finland). The samples were not run in one-assay run to
mimic the real diagnostic procedure. The total assay
variation ranged from 5.8–7.6%.
Subjective well-being during depletion
To determine subjective well-being, the short version of the
SWN [18–20] (Dutch translation) was administered to the
subjects at baseline (D2T0) after the administration of
1,500 mg AMPT (D2T6) and in the prolonged challenge
session, 24 h after the first AMPT dose (D3T24). This scale
with six response categories covers 20 statements on five
subscales (mental functioning, self-control, emotional reg-
ulation, physical functioning, social integration).
Statistical analysis
Statistical analyses concerning the differences in BPND,
SWN scores and PRL levels, at the different time points,
were performed using the non-parametric Wilcoxon test for
paired samples. Spearman’s rho correlation coefficients
were calculated to investigate the relationship between
BPND, SWN scores and PRL levels. A probability value of
0.05 two-tailed was selected as significance level. Statistical
analyses were performed using the Statistical Package for
the Social Sciences (SPSS, release 12.0.1 for Windows).
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Results
Six healthy subjects completed the study. The age (mean ±
standard deviation) of the subjects was 29.3±6.95 years,
respectively. There were three women and three men
included. None of the subjects smoked. After AMPT
administration, no serious adverse events like acute
dystonia or crystalluria were present.
Striatal D2 binding
There was no significant difference in mean BPND binding
at baseline (D1) and 5 h after the administration of
1,500 mg AMPT (D2T5, Fig. 1). The relative change of
mean BPND compared to the baseline after a more prolonged
challenge state (D3T25) with a body-weight-adjusted AMPT
dose ranged between −2.1% and 20.4% with a mean relative
increase of 8.8%±9.0%, which was statistically significant
(n=6, p=0.046, Wilcoxon test for paired samples). In only
one subject, the mean BPND was lower after the more
prolonged challenge procedure than at baseline. In all
subjects, the mean [123I]IBZM binding was higher in the
prolonged challenge state compared to the short challenge
state. There was a significant difference of mean BPND
between the short challenge D2T5 and the more prolonged
challenge D3T25 (p=0.028).
Prolactin
There was a significant increase (p=0.028) of mean PRL
levels from baseline (D2T0, n=6, 10.6±4.3 μg/l) after the
administration of 1,500 mg AMPT at 3 h after the first drug
intake (D2T3, n=6, 89.0±41.8 μg/l; Fig. 2). The levels
decreased subsequently at D2T6 (n=6, 47.2±18.3, p=
0.028; compared with D2T3) in all subjects and stayed
above baseline values (p = 0.028). The PRL levels (n=4,
37.8±12.6) after a body-weight-adjusted AMPT dose, 26 h
after the first drug intake (D3T26), were not significantly
different from baseline (p = 0.068). No correlations were
detected between D2R BPND and PRL levels.
Subjective well-being during dopamine depletion
SWN scores at baseline (D2T0) and after dopamine
depletion (D2T6, D3T24) are displayed in Fig. 3. There
were no differences in SWN scores at baseline and after the
Fig. 1 Effect of alpha-methyl-para-tyrosine (AMPT) on the mean
[123I]IBZM striatal dopamine D2 receptor (D2R)-binding potential
(BPND). The D2R BPND was measured at baseline (D1T0), after the
administration of 1,500 mg AMPT at 5 h after the first drug intake
(D2T5) and after 40 mg AMPT/kg body weight, 25 h after the first
drug intake (D3T25). The mean D2R BPND after 40 mg AMPT/kg was
significantly different from baseline (p=0.046) and D2T5 (p=0.028),
Wilcoxon test for paired samples
Fig. 2 Mean plasma prolactin (PRL, µg/l) levels after alpha-methyl-
para-tyrosine (AMPT) administration. The plasma levels were
measured at baseline (D2T0) after the administration of 1,500 mg
AMPT at 3 h (D2T3) and 6 h (D2T6) after the first drug intake and after
40 mg AMPT/kg body weight, 26 h after the first drug intake (D3T26).
Error bars indicate SEM
Fig. 3 Effect of AMPT on subjective well-being as measured with the
SWN. Mean SWN scores were measured at baseline (D2T0) after the
administration of 1,500 mg AMPT at 6 h after the first drug intake
(D2T6) and after 40 mg AMPT/kg body weight, 24 h after the first
AMPT dose (D3T24). Error bars indicate SEM. mf mental functioning,
er emotional regulation, pf physical functioning. Total and subscales
presented showed a significant AMPT effect, p<0.05; Wilcoxon test
for paired samples
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administration of 1,500 mg AMPT. After prolonged
dopamine depletion, the mean total SWN scores dropped
significantly (p = 0.028) by 31.5±27.6 points compared to
the baseline, indicating a worsening in subjective experi-
ence. There was a significant decline of the subscales
mental functioning (p=0.043), emotional regulation (p=
0.042) and physical functioning (p=0.043). No correlations
were detected between D2R BPND and SWN scores.
Discussion
In this study, we describe induction of acute monoamine
depletion with two alternative procedures to the common
AMPT procedure evaluated with [123I]IBZM SPECT using
relatively low doses of AMPT. We found no change of
mean striatal [123I]IBZM BPND after the first and short
AMPT challenge compared to the baseline. However, this
study showed that AMPT administration (40 mg/kg body
weight, over 25 h) induced a significant increase (+8.8±
9.0%) in measured BPND in six healthy volunteers. For
interpretation of the present work, the following issues must
be considered.
The purpose of monoamine depletion paradigms is to
investigate associations between the function of neuro-
transmitters and neuropsychiatric disorders in humans. The
original AMPT procedure in humans was based on the
assumption of complete synaptic DA depletion [28]. Under
this assumption, the difference between [123I]IBZM SPECT
scans before and after acute DA depletion provides a
measure of the proportion of striatal D2R occupied by
endogenous DA at baseline. In this initial procedure,
AMPT was selected as the depleting agent because this
drug was approved for human use and because AMPT
effects are rapidly reversible. The dose and frequency to
obtain DA depletion were based on findings from previous
studies. In these studies, it was found that doses exceeding
1,000 mg daily result in an enzyme inhibition (tyrosine
hydroxylase) of more than 50% and that stepwise increment
of dosages up to 1,500 mg per day produce marked
increases in inhibition of catecholamine production [29].
Another study showed a decrease of the DA metabolite
homovanillic acid in cerebrospinal fluid with an interval
ranging from 68% to 77% after 4,000 mg AMPT per day
[30]. In these studies, it was also found that higher doses of
AMPT did not induce significantly more inhibition of the
enzyme tyrosine hydroxylase [13, 28]. With a half-life of
about 4 h and a peak plasma concentration of about 2 h
after oral administration, the ingestion of AMPT every 6 h
for 2 days was expected to provide suitable plasma
concentrations at steady state. Therefore, in the original
AMPT procedure, a total dose of 8,000 mg AMPT over
2 days (1 g every 6 h) was administered orally. As in this
study, the subjects presented extrapyramidal symptoms and
as 80% D2R blockade is expected to provoke these
symptoms, depletion was suggested in the 70% to 80%
range [28].
As a lot of adverse effects were reported in the first
depletion studies, Verhoeff et al. [17] reduced the total
amount of administered AMPT to 4,500 mg over 28 h.
Using PET and the radioligand [11C]raclopride, AMPT
resulted in significant increase in D2R BP with a magnitude
comparable with earlier findings, suggesting comparable
changes in striatal DA concentration with lower AMPT
doses. Ever since, administered AMPT dosages in neuro-
imaging challenge studies have been about 4,500 mg over
2 days. Nevertheless, though the following studies did not
administer the total dose of 8,000 mg AMPT, side effects
and study withdrawal were still a dilemma [14].
The occurrence of side effects due to these relatively
high doses (4,500 to 8,000 mg) and the knowledge that
AMPT does not completely block tyrosine hydroxylase [13,
28] raise the question of the necessity of maximum DA
depletion to study the dysregulation of the DA system. We
belief that a depletion paradigm is equally valuable to
investigate whether patients with different neuropsychiatric
disorders differ in the response to an adequate DA
challenge. This requires that the effect of AMPT on striatal
[123I]IBZM BPND should at least be significant and reliable.
Although the magnitude of the AMPT-induced change of
striatal [123I[IBZM BPND in our sample is small, the change
is significant. Moreover, our findings are in accordance
with the findings of an IBZM SPECT study that showed a
significant AMPT effect on mean striatal BPND (+9%±7%)
in a sample of 18 healthy subjects with comparable mean
age (31±8 years), receiving a total dose of 8,000 mg
AMPT, over 48 h [5]. Besides, studies have demonstrated
that the between-study variability in the AMPT effect in
general is quite large. For example, in other PET and
SPECT studies in healthy subjects, with 4,000–8,000 mg
AMPT over 48 h, mean differences in striatal D2R BPND
ranged from +13% to +28% [17, 28, 31, 32]. The between-
subject variability in the present study is large as well
(ranges from −2.1% and 20.4%), which is also in agreement
with findings by others. It has to be taken into account that
these studies did not employ the same instrumentation and
methodology. However, to our best knowledge, test–retest
variability using the bolus plus constant infusion paradigm
with IBZM SPECT after AMPT challenge has not been
reported yet. Therefore, similarities and differences in the
AMPT effect in the mentioned studies should be interpreted
with caution.
Thus, our data suggest that, to induce acute DA
depletion to measure acute changes in striatal synaptic DA
concentration in vivo, this procedure with relative low
doses of AMPT is a suitable alternative to the common
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AMPT procedure. The probability of side effects and study
withdrawal can be reduced by this procedure. However, it is
uncertain if the magnitude of striatal DA depletion achieved
by this regimen is equally sufficient to demonstrate
dysfunction of neurotransmitters in neuropsychiatric disor-
ders as the original AMPT procedure. Future studies using
this paradigm in psychiatric populations should address this
issue. Moreover, although our present results (particularly
the results obtained with the AMPT challenge adjusted for
bodyweight) suggest that we induced a significant reduc-
tion of DA concentrations, including striatal synaptic DA,
we do not know the extent of this reduction. As we did not
observe extrapyramidal side effects, striatal DA depletion
may be less than 70–80%. Additional studies are needed to
estimate the actual depletion of striatal DA concentrations,
which could be induced with this novel procedure. To do
so, it might be of value to measure plasma AMPT levels in
humans and induce comparable plasma levels in small
laboratory animals. In the same animal experiment, micro-
dialysis can be performed to assess the actual extracellular
striatal DA concentrations. Although such a strategy can be
used to estimate the effects on extracellular DA levels, it
does not reflect changes on the synaptic level (for a
discussion, see Schiffer et al. [33]). Alternatively, one
may estimate the depletion by measures of the predominant
DA metabolite homovanillic acid (HVA) in cerebrospinal
fluid in humans, but it is expected that the magnitude of DA
depletion is larger than HVA depletion [5].
In agreement with previous studies applying the AMPT
paradigm in healthy volunteers [17, 29, 34, 35], AMPT
administration increased serum PRL levels significantly
shortly after its first administration, and PRL levels fell
thereafter, even though more AMPT was administered.
AMPT-induced DA depletion consistently produced a two-
to ninefold increase in PRL levels [17, 29, 34, 35].
Previously, PRL has been used as a marker of the
effectiveness of AMPT as an inhibitor of endogenous DA
synthesis [35] because hypothalamic DA is known to
inhibit PRL release at the level of the pituitary gland [36].
However, DA is not the only factor controlling PRL levels,
and there is no direct relation between hypophysial stalk
DA levels and serum PRL levels [36]. Thus, our findings,
taken together with the results from the mentioned studies,
suggest that, though an initial PRL response indicates acute
DA depletion, it may not be a useful indicator of the
adequacy of DA depletion in striatum.
Subjective experience worsened in the prolonged proce-
dure, with effect on mental functioning, emotional regula-
tion and physical functioning, as measured by the SWN
scale. From studies with antipsychotics, we know that
antagonism of dopaminergic neurotransmission is relevant
for subjective experience, and higher striatal D2R occu-
pancy by antipsychotics is related to worse subjective
experience [37]. These type of subjective side effects have
been labeled as ‘neuroleptic dysphoria’ [38] or neuroleptic-
induced anhedonia [20]. In addition, subjective well-being
during antipsychotic medication is associated with medica-
tion compliance [37], and discomfort is reason for study
withdrawal in AMPT challenge studies [5, 39]. Thus,
although a relatively low dose of AMPT was administered,
subjective well-being worsened. Nevertheless, all the
subjects completed the study, in contrast to some other
AMPT challenge studies using higher AMPT doses.
The results of the present study should be interpreted in
light of the following considerations. The order of scanning
and depletion was not randomized. Therefore, we cannot
rule out a time or order effect. In addition, the sample size
is limited; however, the effect exceeds p<0.05. Also,
compared to PET, clinical SPECT investigations have the
disadvantage of lower resolution. Finally, our findings will
need to be replicated in independent studies.
In conclusion, this study demonstrates that a relatively
low, body-weight-adjusted AMPT dose effectively reduced
dopamine concentration in the brain. The probability of
dose-related severe side effects and study withdrawal can
be reduced by this procedure. Moreover, this safe and
well-tolerated pharmacological challenge appears to be
well-suited to study the relationship between the catechol-
aminergic function and neuropsychiatric conditions in
future studies using neuropsychological tasks and func-
tional neuroimaging.
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